Buyer Name: NHS England
Buyer Address: Wellington House, 133-135 Waterloo Rd, London, UKI45, SE1 8UG, United Kingdom
Contact Email: katie.noonan@nhs.net
NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin
Buyer Contact Info
Status
complete
complete
Procedure
open
open
Value
25881000.0 GBP
25881000.0 GBP
Published
30 Jan 2026, 09:48
30 Jan 2026, 09:48
Deadline
n/a
n/a
Contract Start
01 Feb 2026, 00:00
01 Feb 2026, 00:00
Contract End
30 Sep 2027, 22:59
30 Sep 2027, 22:59
Category
n/a
n/a
CPV
33600000 - Pharmaceutical products
33600000 - Pharmaceutical products
Region
n/a
n/a
Awarded To
ZENTIVA PHARMA UK LIMITED, THORNTON & ROSS LIMITED, TEVA UK LIMITED, GLENMARK PHARMACEUTICALS EUROPE LIMITED, Farmak Pharmaceuticals UK Ltd, DR REDDY'S LABORATORIES (UK) LIMITED, CELIX PHARMA LTD, AMAROX LIMITED, ACCORD-UK LTD
ZENTIVA PHARMA UK LIMITED, THORNTON & ROSS LIMITED, TEVA UK LIMITED, GLENMARK PHARMACEUTICALS EUROPE LIMITED, Farmak Pharmaceuticals UK Ltd, DR REDDY'S LABORATORIES (UK) LIMITED, CELIX PHARMA LTD, AMAROX LIMITED, ACCORD-UK LTD
Official Source
Open Find a Tender
Open Find a Tender
Description
Project title: NHS National Framework for Transition Products (Apremilast, Pazopanib and Dapagliflozin) commencing 1st February 2026 Offer reference number: CM/TNS/25/5735 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin Lot 1 DLN/DNW: 01/02/2026 to 31/01/2027 (12 months) Lot 2 DLS/DNE: 01/02/2026 to 31/01/2027 (12 months) Lot 3 DCE/DSW: 01/02/2026 to 30/09/2027 (20 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Linked Documents
Select a document to preview.
Opportunity Context
Lots
Lot 1 Status: complete
Documents
Document Description: Not published
Contracts
Contract Title: Lot 1 - CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin
Raw Notice JSON
Expand raw payload
{
"awards": [
{
"id": "2",
"items": [
{
"additionalClassifications": [
{
"description": "Pharmaceutical products",
"id": "33600000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"country": "GB",
"countryName": "United Kingdom",
"region": "UKC"
},
{
"country": "GB",
"countryName": "United Kingdom",
"region": "UKD"
},
{
"country": "GB",
"countryName": "United Kingdom",
"region": "UKF"
},
{
"country": "GB",
"countryName": "United Kingdom",
"region": "UKG"
},
{
"country": "GB",
"countryName": "United Kingdom",
"region": "UKH"
},
{
"country": "GB",
"countryName": "United Kingdom",
"region": "UKJ"
},
{
"country": "GB",
"countryName": "United Kingdom",
"region": "UKK"
}
],
"id": "1",
"relatedLot": "1"
}
],
"mainProcurementCategory": "goods",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-COH-02158996",
"name": "ZENTIVA PHARMA UK LIMITED"
},
{
"id": "GB-COH-00185947",
"name": "THORNTON \u0026 ROSS LIMITED"
},
{
"id": "GB-COH-00302461",
"name": "TEVA UK LIMITED"
},
{
"id": "GB-COH-05040260",
"name": "GLENMARK PHARMACEUTICALS EUROPE LIMITED"
},
{
"id": "GB-COH-15398948",
"name": "Farmak Pharmaceuticals UK Ltd"
},
{
"id": "GB-COH-01729064",
"name": "DR REDDY\u0027S LABORATORIES (UK) LIMITED"
},
{
"id": "GB-COH-12474195",
"name": "CELIX PHARMA LTD"
},
{
"id": "GB-COH-10997632",
"name": "AMAROX LIMITED"
},
{
"id": "GB-COH-00079585",
"name": "ACCORD-UK LTD"
}
]
}
],
"buyer": {
"id": "GB-PPON-PDPT-3135-BWWY",
"name": "NHS England"
},
"contracts": [
{
"aboveThreshold": true,
"awardID": "2",
"dateSigned": "2026-01-05T00:00:00Z",
"documents": [
{
"description": "CONTRACT COPY Documents UK7 Contract Details Notice - CM-TNS-25-5735",
"documentType": "contractSigned",
"format": "application/pdf",
"id": "A-11216",
"url": "https://www.find-tender.service.gov.uk/Notice/Attachment/A-11216"
},
{
"datePublished": "2026-01-30T09:48:08Z",
"description": "Contract details notice on Find a Tender",
"documentType": "contractNotice",
"format": "text/html",
"id": "008310-2026",
"noticeType": "UK7",
"url": "https://www.find-tender.service.gov.uk/Notice/008310-2026"
}
],
"hasRenewal": true,
"id": "2",
"period": {
"endDate": "2027-09-30T23:59:59+01:00",
"maxExtentDate": "2029-09-30T23:59:59+01:00",
"startDate": "2026-02-01T00:00:00Z"
},
"renewal": {
"description": "Option or options to extend (at the discretion of the Authority) up to a maximum of 24 months"
},
"status": "active",
"title": "Lot 1 - CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin",
"value": {
"amount": 25881000.0,
"amountGross": 31057200.0,
"currency": "GBP"
}
}
],
"date": "2026-01-30T09:48:08Z",
"id": "008310-2026",
"initiationType": "tender",
"language": "en",
"ocid": "ocds-h6vhtk-05936a",
"parties": [
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "SE1 8UG",
"region": "UKI45",
"streetAddress": "Wellington House, 133-135 Waterloo Rd"
},
"contactPoint": {
"email": "katie.noonan@nhs.net"
},
"details": {
"classifications": [
{
"description": "Public authority - central government",
"id": "publicAuthorityCentralGovernment",
"scheme": "UK_CA_TYPE"
}
],
"url": "https://www.england.nhs.uk/"
},
"id": "GB-PPON-PDPT-3135-BWWY",
"identifier": {
"id": "PDPT-3135-BWWY",
"scheme": "GB-PPON"
},
"name": "NHS England",
"roles": [
"buyer"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Devon",
"postalCode": "EX32 8NS",
"region": "UKK43",
"streetAddress": "Whiddon Valley"
},
"contactPoint": {
"email": "hospmsg@accord-healthcare.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-00079585",
"identifier": {
"id": "00079585",
"scheme": "GB-COH"
},
"name": "ACCORD-UK LTD",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Harrow",
"postalCode": "HA1 2EN",
"region": "UKI74",
"streetAddress": "Congress House 14 Lyon Road"
},
"contactPoint": {
"email": "vikas.dahiya@amaroxpharma.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "sme",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-10997632",
"identifier": {
"id": "10997632",
"scheme": "GB-COH"
},
"name": "AMAROX LIMITED",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "E16 2DQ",
"region": "UKI41",
"streetAddress": "12 Constance Street"
},
"contactPoint": {
"email": "customer.service@celixpharma.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "sme",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-12474195",
"identifier": {
"id": "12474195",
"scheme": "GB-COH"
},
"name": "CELIX PHARMA LTD",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Cambridge",
"postalCode": "CB4 0PE",
"region": "UKH12",
"streetAddress": "410 Cambridge Science Park Milton Road"
},
"contactPoint": {
"email": "drlukhospital@drreddys.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-01729064",
"identifier": {
"id": "01729064",
"scheme": "GB-COH"
},
"name": "DR REDDY\u0027S LABORATORIES (UK) LIMITED",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Hull",
"postalCode": "HU1 1UU",
"region": "UKE11",
"streetAddress": "47 Queen Street"
},
"contactPoint": {
"email": "info@farmak.uk"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "sme",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-15398948",
"identifier": {
"id": "15398948",
"scheme": "GB-COH"
},
"name": "Farmak Pharmaceuticals UK Ltd",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Harrow",
"postalCode": "HA3 0BU",
"region": "UKI72",
"streetAddress": "2-B Laxmi House"
},
"contactPoint": {
"email": "eva.roche@glenmarkpharma.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-05040260",
"identifier": {
"id": "05040260",
"scheme": "GB-COH"
},
"name": "GLENMARK PHARMACEUTICALS EUROPE LIMITED",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Castleford",
"postalCode": "WF10 5HX",
"region": "UKE45",
"streetAddress": "Ridings Point"
},
"contactPoint": {
"email": "chrissie.kellett@tevauk.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-00302461",
"identifier": {
"id": "00302461",
"scheme": "GB-COH"
},
"name": "TEVA UK LIMITED",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Huddersfield",
"postalCode": "HD7 5QH",
"region": "UKE44",
"streetAddress": "Linthwaite Labs Manchester Road"
},
"contactPoint": {
"email": "hospitalcontracts@thorntonross.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-00185947",
"identifier": {
"id": "00185947",
"scheme": "GB-COH"
},
"name": "THORNTON \u0026 ROSS LIMITED",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "EC4A 1JP",
"region": "UKI31",
"streetAddress": "12 New Fetter Lane"
},
"contactPoint": {
"email": "ukcustomerservices@zentiva.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-02158996",
"identifier": {
"id": "02158996",
"scheme": "GB-COH"
},
"name": "ZENTIVA PHARMA UK LIMITED",
"roles": [
"supplier"
]
}
],
"tag": [
"award",
"contract"
],
"tender": {
"coveredBy": [
"GPA"
],
"description": "Project title: NHS National Framework for Transition Products (Apremilast, Pazopanib and Dapagliflozin) commencing 1st February 2026\nOffer reference number: CM/TNS/25/5735\nPeriod of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months.\nPotential periods of call-offs under the framework agreement: \nCM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin \nLot 1 DLN/DNW: 01/02/2026 to 31/01/2027 (12 months) \nLot 2 DLS/DNE: 01/02/2026 to 31/01/2027 (12 months) \nLot 3 DCE/DSW: 01/02/2026 to 30/09/2027 (20 months)\nPublished By: Medicines Procurement and Supply Chain - NHS Medicines Value \u0026 Access, NHS England",
"documents": [
{
"description": "Not published",
"documentType": "conflictOfInterest",
"id": "conflictOfInterest"
}
],
"id": "C386886",
"legalBasis": {
"id": "2023/54",
"scheme": "UKPGA",
"uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
},
"lots": [
{
"id": "1",
"status": "complete"
}
],
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"status": "complete",
"techniques": {
"frameworkAgreement": {
"description": "Please refer to the ITO Documents for the Operation Description",
"method": "withReopeningCompetition",
"type": "closed"
},
"hasFrameworkAgreement": true
},
"title": "NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin"
}
}